Astrana Health(US:ASTH)2025-08-07 21:30Financial Performance - Q2 2025 - Revenue reached $654.8 million[9], a 35% increase compared to Q2 2024's $486.3 million[30] - Adjusted EBITDA was $48.1 million[9], slightly up from $47.917 million in Q2 2024[30] - Net income attributable to Astrana Health was $9.4 million[9], compared to $19.171 million in Q2 2024[30] - EPS-Diluted was $0.19[9], down from $0.40 in Q2 2024[30] FY2025 Guidance - Total revenue is projected to be in the range of $3.1 billion to $3.3 billion[11] - Adjusted EBITDA is expected to be between $215 million and $225 million[11] Business Growth & Risk Management - Astrana Health now serves over 1.6 million patients in value-based arrangements following the acquisition of Prospect[13] - Care Partners segment has 1.4 million members pro forma[13] - 78% of revenues are from fully capitated arrangements, compared to 60% a year ago[13] - The company anticipates 75-85% of capitation revenue from full-risk arrangements exiting 2025[20]